BioSpace News Archive

Drug Development

Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting

Samus Therapeutics, Inc. (“Samus” or the “Company”), today announced a poster presentation addressing the Company’s Phase 1 study evaluating orally administered PU-H71 with ruxolitinib in patients with myelofibrosis no longer fully responsive to orally administered ruxolitinib.

December 9, 2019
·
4 min read
Drug Development

Kymera Therapeutics to Present Preclinical Data Demonstrating Potent Antitumor Activity by a Selective STAT3 Degrader in Hematologic Malignancies at the American Society of Hematology Annual Meeting

Kymera Therapeutics Inc., today announced the company will present new preclinical data showing the further characterization of novel, highly selective and potent degraders of STAT3 with activity across multiple hematologic malignancies including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL),

December 9, 2019
·
3 min read
Deals

Clinical Innovations strengthens commitment to NICU with acquisition of SweetUms, BoogieBaby products

Labor and Delivery and NICU market leader expands product offering in the NICU

December 9, 2019
·
4 min read
Biotech Beach

IntelliGuard™ Announces Integration of IntelliGuard Anesthesia with Epic Systems

IntelliGuard™, the global leader in RFID medication management technology, today announced the integration of its IntelliGuard Anesthesia solution with Epic, one of the world’s largest electronic medical record providers

December 9, 2019
·
4 min read
Business

PanTheryx Bovine Colostrum Recognized as GRAS

Independent expert panel recognizes gut and immune supporting ingredient from leading biotechnology company as Generally Recognized as Safe (GRAS)

December 9, 2019
·
2 min read
Biotech Beach

Biocept Announces Pricing of $10.0 Million Underwritten Public Offering

Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $10.0 million.

December 9, 2019
·
4 min read
Drug Development

Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported new data from the extension phase of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency at the 2019 American Society of Hematology (ASH) Annual Meeting.

December 9, 2019
·
10 min read
Drug Development

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020

December 9, 2019
·
11 min read
Drug Development

Astex Pharmaceuticals Presents Topline Data from the ASCERTAIN Phase 3 Study of its Novel, Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.

The study achieved its primary objective of decitabine systemic exposure equivalence between oral ASTX727 and IV decitabine with an oral/IV ratio of approximately 99%

December 9, 2019
·
8 min read
Global Glaucoma Surgery Devices Market 2019-2023| Evolving Opportunities with ALLERGAN and Carl Zeiss Meditec | Technavio

Technavio has announced its latest market research report titled global glaucoma surgery devices market 2019-2023

December 9, 2019
·
5 min read